Skip to content

Long-Term Debt at other companies

Eli Lilly logo
Eli LillyLLY
$39.37B+14.1%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$36.09M+74.5%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$570.41M+0.6%
uniQure logo
uniQureQURE
$49.94M-3.2%
Precigen logo
PrecigenPGEN
$93.52M
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
$10.13B+49.9%

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LongTermNotesPayable.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's long-term debt?
Perspective Therapeutics (CATX) reported long-term debt of $1.55M in Q1 2026.
How has Perspective Therapeutics's long-term debt changed year-over-year?
Perspective Therapeutics's long-term debt decreased by 3.5% year-over-year, from $1.61M to $1.55M.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.